Nexalin reports Brazil trial gains in anxiety, depression and sleep, plus U.S. patent protection through 2042.
Nexalin Technology Inc.
(NASDAQ:NXL) on Wednesday reported clinical trial results in Brazil.
The trial showed improvements in anxiety, depression, insomnia, and quality-of-life measures, supporting its drug-free neurostimulation approach.
Anxiety Response Reached 77.8% Nexalin said an 8-week clinical trial in Brazil showed a 77.8% anxiety response rate.
The rate applied to adults with generalized anxiety disorder and comorbid insomnia at the end of treatment.
GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8
NeuroXess eyes mass BCI production with new unit coming online in H2
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker
N-Zyme Biomedical Begins Phase 2 Trial of First Pepsin Inhibitor for Reflux Disease
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
China approves first commercial brain-computer interface as NeuroXess trials begin
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Study that highlights Nevisense potential for prediction of AD published in leading journal
Belfast health-tech company Neurovalens has received ‘de novo’ approval from the US FDA for its prescribed treatment for symptoms…
NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into human trials.
Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026
GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8
TORONTO, ON / ACCESS Newswire / May 21, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial…
NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise capital for growth and…
